Kleiner Perkins

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.

NewLimit focuses on developing epigenetic reprogramming medicines to treat age-related diseases and extend the human health span. It uses single-cell genomics, machine learning, and functional assays to identify epigenetic targets and develop messenger RNA-based therapies for improving metabolic function in liver cells.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.

Founded in 2018, Neuron23 is a biotechnology company based in South San Francisco, California, with an additional office in Munich, Germany. It specializes in developing and manufacturing medicines for genetic disorders using artificial intelligence technology and genetics.

Helix is a leading population genomics company that operates at the intersection of clinical care, research, and genomics. Its comprehensive platform enables healthcare systems, life sciences companies, and payers to advance genomic research and integrate genomic data into clinical care.

Vera Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2016 and formerly known as Trucode Gene Repair, Inc. The company focuses on developing innovative biologic therapeutics with the potential to transform treatment for patients suffering from serious immunological diseases and genetic disorders. Its lead product candidate, atacicept, is a fusion protein administered as a subcutaneous injection once weekly, designed to inhibit factors that stimulate the production of autoantibodies associated with autoimmune diseases. Additionally, Vera Therapeutics is utilizing gene-editing technology aimed at addressing conditions such as sickle cell disease and cystic fibrosis, striving to enhance gene detection and regulation for improved patient outcomes.

Founded in 2018, Neuron23 is a biotechnology company based in South San Francisco, California, with an additional office in Munich, Germany. It specializes in developing and manufacturing medicines for genetic disorders using artificial intelligence technology and genetics.

Founded in 2018, Neuron23 is a biotechnology company based in South San Francisco, California, with an additional office in Munich, Germany. It specializes in developing and manufacturing medicines for genetic disorders using artificial intelligence technology and genetics.

ArsenalBio is a programmable cell therapy company established in 2019, focused on developing and commercializing innovative immune cell therapies, particularly for cancer treatment. The company utilizes advanced technologies, including CRISPR-based genome engineering, synthetic biology, and machine learning, to create multifunctional T-cell therapies. ArsenalBio's approach involves the precise insertion of large synthetic DNA sequences, enabling the generation of next-generation autologous T-cell therapies. By integrating these cutting-edge methods, ArsenalBio aims to enhance the effectiveness and safety of immune cell therapies, reduce costs for healthcare providers, and improve market access, ultimately broadening patient outcomes and making these therapies more widely available.

Vera Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2016 and formerly known as Trucode Gene Repair, Inc. The company focuses on developing innovative biologic therapeutics with the potential to transform treatment for patients suffering from serious immunological diseases and genetic disorders. Its lead product candidate, atacicept, is a fusion protein administered as a subcutaneous injection once weekly, designed to inhibit factors that stimulate the production of autoantibodies associated with autoimmune diseases. Additionally, Vera Therapeutics is utilizing gene-editing technology aimed at addressing conditions such as sickle cell disease and cystic fibrosis, striving to enhance gene detection and regulation for improved patient outcomes.

Tmunity Therapeutics, Inc. is a biotherapeutics company based in Philadelphia, Pennsylvania, that specializes in the development of innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, Tmunity focuses on harnessing the potential of T cells through novel technologies, including T Cell Receptor (TCR) engineered T cells and regulatory T cells (Treg). The company has developed advanced platforms that allow for precise control over T cell activation and direction in vivo, as well as proprietary methods for activating, expanding, and genetically engineering T cells sourced from peripheral blood, cord blood, and tumors. Tmunity aims to advance personalized next-generation immunotherapies and has a team of experts with extensive experience in T-cell biology and clinical development, enhancing its capability to conduct safe and effective clinical trials. Its robust manufacturing platform supports multi-center clinical studies across various therapeutic areas, positioning Tmunity at the forefront of immunotherapy innovation.

Helix is a leading population genomics company that operates at the intersection of clinical care, research, and genomics. Its comprehensive platform enables healthcare systems, life sciences companies, and payers to advance genomic research and integrate genomic data into clinical care.

Helix is a leading population genomics company that operates at the intersection of clinical care, research, and genomics. Its comprehensive platform enables healthcare systems, life sciences companies, and payers to advance genomic research and integrate genomic data into clinical care.

Founded in 2012, VoloAgri Group specializes in plant genetics and hybrid vegetable breeding services. With operations across North America, Europe, and the Middle East, they focus on improving agricultural results through advanced breeding technologies while promoting sustainable practices.

Founded in 2012, VoloAgri Group specializes in plant genetics and hybrid vegetable breeding services. With operations across North America, Europe, and the Middle East, they focus on improving agricultural results through advanced breeding technologies while promoting sustainable practices.

Veracyte is a global genomic diagnostics company that improves patient care by providing genomic tests to inform diagnosis and treatment decisions. Its portfolio includes tests for thyroid, lung, breast cancer, idiopathic pulmonary fibrosis, and prostate cancer, with more in development.

OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

Veracyte is a global genomic diagnostics company that improves patient care by providing genomic tests to inform diagnosis and treatment decisions. Its portfolio includes tests for thyroid, lung, breast cancer, idiopathic pulmonary fibrosis, and prostate cancer, with more in development.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Veracyte is a global genomic diagnostics company that improves patient care by providing genomic tests to inform diagnosis and treatment decisions. Its portfolio includes tests for thyroid, lung, breast cancer, idiopathic pulmonary fibrosis, and prostate cancer, with more in development.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

Navigenics, Inc. specializes in personalized genetics testing and health counseling services aimed at educating individuals and their physicians about genetic predispositions. The company provides genetic information and analysis to empower clients to take proactive measures to prevent disease, facilitate early diagnosis, and effectively manage health conditions. Navigenics delivers its services through a network of medical centers and physicians, as well as employer wellness programs at leading corporations. By motivating individuals to act on their genetic insights, Navigenics seeks to enhance overall health outcomes and reduce the impact of potential diseases.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Navigenics, Inc. specializes in personalized genetics testing and health counseling services aimed at educating individuals and their physicians about genetic predispositions. The company provides genetic information and analysis to empower clients to take proactive measures to prevent disease, facilitate early diagnosis, and effectively manage health conditions. Navigenics delivers its services through a network of medical centers and physicians, as well as employer wellness programs at leading corporations. By motivating individuals to act on their genetic insights, Navigenics seeks to enhance overall health outcomes and reduce the impact of potential diseases.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

CardioDx, Inc. is a molecular diagnostics company based in Redwood City, California, specializing in cardiovascular genomic diagnostics. Founded in 2003, the company develops clinically validated tests aimed at improving the assessment and management of cardiovascular diseases, including coronary artery disease (CAD), cardiac arrhythmias, and heart failure. One of its key products is the Corus CAD test, a blood-based gene expression test designed to help primary care clinicians and cardiologists determine whether a non-diabetic patient's chest discomfort or other symptoms are indicative of obstructive CAD. By utilizing genomic technologies, CardioDx provides healthcare professionals with actionable information to enhance treatment decisions and patient outcomes while potentially reducing healthcare costs. The company primarily serves customers in the United States.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

NewLimit focuses on developing epigenetic reprogramming medicines to treat age-related diseases and extend the human health span. It uses single-cell genomics, machine learning, and functional assays to identify epigenetic targets and develop messenger RNA-based therapies for improving metabolic function in liver cells.